Epigenomics AG: Epigenomics Further Strengthens Intellectual Property Coverage for Epi proColon in the U.S. and in China

Berlin (Germany) and Germantown, MD (U.S.A.), February 10, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX; OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company was granted key Intellectual Property (IP) rights related to its blood-based colorectal cancer screening test Epi proColon(R) in the U.S. and in China.

On January 7, 2014, the Company received a patent for the method used in Epi proColon(R) to analyse Septin9 DNA methylation by the United States Patent and Trademark Office (USPTO).

In addition, on January 30, 2014, Epigenomics received a ‘Notice of Allowance’ stating that the Chinese Patent and Trademark Office intends to grant a patent for Epigenomics’ Septin9 DNA methylation biomarker (mSEPT9) for use in the diagnosis of colorectal cancer. The Company was granted the corresponding biomarker patents for the U.S. by the USPTO already in 2010 and for Europe by the European Patent Office (EPO) in 2008.

‘Receiving the patent for the underlying method used in our Epi proColon(R) screening test in the U.S. and the notice of allowance for the Septin9 biomarker in China significantly strengthens our intellectual property portfolio for our key product in two of the world’s biggest markets,’ Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented. ‘The method patent in the U.S. extends the IP coverage for Epi proColon(R) beyond the existing protection for the Septin9 biomarker used for colorectal cancer screening. This is especially encouraging in light of the recent Mayo vs. Prometheus court ruling in the US and underscores our leadership in molecular diagnostics based on DNA methylation. The recent patent grants are in line with our strategy to protect our products at different levels and are part of multiple biomarker and method patent applications we have filed over the past years to cover novel DNA methylation biomarkers in many cancer indications. The current grants further validate the innovative nature of our Septin9-based colorectal cancer test.’

– Ends –

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel. +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876

pr@epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon(R), is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is under regulatory review by the FDA for the U.S.A. Additionally, the company markets its tissue assay for use in lung cancer diagnosis, Epi proLung(R), in Europe. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.